Skin displacement analysis (SDA): a tool for the quantitative evaluation of skin movements elicited by underlying muscles in the face and neck area by Proebstle, Thomas M
© 2011 Proebstle, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical, Cosmetic and Investigational Dermatology 2011:4 27–33
Clinical, Cosmetic and Investigational Dermatology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
27
OrIgInAL reseArCh
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/CCID.S18185
skin displacement analysis (sDA): a tool for the 
quantitative evaluation of skin movements elicited 
by underlying muscles in the face and neck area
Thomas M Proebstle
Department of Dermatology, 
University Clinic of Mainz,  
Mainz, germany
Correspondence: Thomas M Proebstle 
Private Clinic Proebstle, P6, 26 (Auf den 
Planken), D-68161 Mannheim, germany 
Tel +49 621 3069600 
Fax +49 621 3069601 
email thomas.proebstle@web.de
Background: Quantitative numerical analysis of skin displacement triggered by muscles 
inserting the overlaying skin would be useful for monitoring the inhibition of mimetic 
muscles.
Methods: By using removable grid markings and digital photographs, skin displacement 
analysis (SDA) was performed on 13 patients pre-treatment and on Days 1, 2, 3, and 7 after 
injection of 18 units of botulinum toxin type A (BoNT/A) in the fronto-glabellar area.
Results: At baseline, amplitudes of horizontal skin displacement with fronto-glabellar 
contraction showed a linear increase along the eyebrow laterally from the midline; mean 
values (±standard deviation [SD]) 15 and 30 mm lateral to the midline were 3.2 ± 1.0 mm 
(range, 1.9–4.9 mm) and 6.5 ± 1.4 mm (range 4.0–8.5 mm), respectively. After injection of 
BoNT/A, maximum horizontal skin displacement 30 mm lateral to the midline showed a mean 
reduction (±SD) to 62% ± 23% at Day 2 and to 17% ± 16% at Day 7; corresponding values 
15 mm lateral to the midline were 62% ± 29% and 15% ± 20%, respectively. In all cases, the 
reduction in horizontal skin displacement compared with pre-injection levels was statistically 
significant (P , 0.001).
Conclusion: SDA is a feasible method for the quantitative evaluation of skin movements 
elicited by muscles inserting the overlaying skin in the face and neck area.
Keywords: botulinum toxin type A, fronto-glabellar contraction, skin displacement analysis, 
glabellar lines
Introduction
Injection of botulinum toxin type A (BoNT/A) is a frequently administered aesthetic 
treatment for the reduction or prevention of hyperkinetic facial lines and rhytids. 
However, since the introduction of BoNT/A to aesthetic medicine,1 studies evaluating 
the effects of this treatment have predominantly relied on semi-quantitative evaluation 
tools, such as the rating scale for hyperkinetic facial lines, as proposed by Kim et al2 
or other self-designed analog scores adapted to the specific design of their associated 
studies.3,4 Even in recent trials, semi-quantitative analog scale-derived analyses of 
subjects’ and investigators’ subjective perceptions were used for comparing differences 
between injection volumes and dilutions5 and for comparing BoNT/A versus BoNT/A 
with epinephrine.6
The reference method for quantitative evaluation of the BoNT/A blocking action 
on skeletal muscle in neurology is electromyography. While quantitative analysis of 
BoNT/A efficacy with evaluation of the compound muscle action potential (CMAP) 
M-wave7 seems reasonable in neurological diseases, the spatial resolution, in general, Clinical, Cosmetic and Investigational Dermatology 2011:4
Figure 1 A) Pre-treatment patient with relaxed fronto-glabellar area and a removable 
5 mm grid on the central and right frontal region. numbers indicate the injection sites 
with corresponding number of BonT/A units injected. B) relaxed muscle tension. 
The point of interest 30 mm lateral to the midline, immediately above the eyebrow, 
was marked with two perpendicular black lines, coordinates (X2; Y2). The reference 
point of the geometric system at the inner canthus of the right eye was marked 
(X1; Y1) and subtracted from any point of interest for the purpose of calibration. 
C) Maximum fronto-glabellar contraction with otherwise identical markings as in 
Figure 1B. The horizontal movement of the point of interest from Figure 1B (relaxed) 
to Figure 1C (contraction) was calculated in pixels as ∆X = [(X2 contraction − X1) − 
(X2 relaxed − X1)].
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is too limited for distinctive monitoring of BoNT/A efficacy 
in aesthetics. Despite this, it has recently been proposed for 
follow-up of global BoNT/A action on the frontalis muscle.8 
To date, quantitative image analyses of the aesthetic effects of 
BoNT/A have been limited to the evaluation of the eyebrow 
height or eyebrow mobility after injections into the glabellar 
area, with respect to the mid-pupillary line or to directly 
related nearby locations.9,10
To overcome some of the above-mentioned   limitations 
of current quantitative image analyses, and to avoid 
semi-  quantitative  analog  scale-based  methods  and 
electromyography, a new quantitative, two-dimensional 
method – skin displacement analysis (SDA) – with a high 
resolution of a few millimeters is presented here. It is 
applicable to almost any given place in the face and neck 
area. Specifically, the proof-of-principle of the method is 
demonstrated by analysis of skin displacement before and 
after BoNT/A injection in the fronto-glabellar area.
Methods
study design
Consenting individuals requesting routine fronto-glabellar 
BoNT/A injections were treated with BoNT/A at a 
  standardized dosage. Patients were marked on the right and 
central frontal area with a removable 0.25 cm² grid (Thermage 
Inc, Hayward, CA, USA), thus providing a length of 5 mm 
between 2 crossings (Figure 1A). Facial photo-documentation 
was carried out pre-treatment (Day 0) and during the week 
after administration of the toxin (Days 1, 2, 3, and 7), as 
described below. The grid was placed immediately before 
each measurement and removed afterwards.
Injection pattern of BonT/A
Each 100 unit vial of lyophilized BoNT/A (Xeomin®, Merz 
Pharmaceuticals, Frankfurt, Germany) was dissolved in 
2.5 mL physiological saline and then injected intramuscularly 
using a 0.3 mL insulin syringe with an 8 mm 30G needle. 
This purified BoNT/A preparation is free from complexing 
proteins, has demonstrated equivalence to the first market-
available BoNT/A preparation for efficacy and duration of 
action,11 and has shown a lack of development of neutralizing 
antibodies in preclinical studies.12 In total, 18 units of 
BoNT/A were injected into the fronto-glabellar area and 
6 units were injected laterally to both eyebrows (Figure 1A). 
First, 4 units were injected in the midline into the central 
part of the procerus, followed by 2 units 15 mm above this 
(Figure 1A). Three units were then injected 10 mm above 
and 15 mm laterally to the first procerus injection, into the 
medial parts of right and left corrugator supercilii close to the 
medial ending of the eyebrow (Figure 1A); another 3 units 
were injected 15 mm laterally and 5 mm above this injection 
(Figure 1A). Finally, 3 units were injected into the orbital rim, 
immediately at the lateral end of the eyebrows into the lateral 
and upper parts of the orbicularis oculi (Figure 1A).Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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skin displacement analysis
Horizontal skin displacement due to maximum contraction of 
the fronto-glabellar area was analyzed at Day 0 immediately 
before the injection of BoNT/A, and at Days 1, 2, 3, and 
7 post-injection. Figure 1B shows a patient with relaxed 
fronto-glabellar muscle tonus and the removable marking 
grid in place with an additionally drawn midline.   Vertical and 
  horizontal black lines cross at the medial canthus of the right 
eye (X1, Y 1), which serves as the fixed-point of the geometric 
system, thereby allowing shifts or movements of the face at 
other points to be calculated from a   standardized reference 
point. Vertical and horizontal black lines also cross at one 
sample point of interest above the right eyebrow (X2, Y2). 
The same 2 points are marked during maximum fronto-
  glabellar contraction, as shown in   Figure 1C. The horizontal 
shift of the point of interest above the eyebrow   during 
  maximum fronto-glabellar contraction (X2 contraction; 
  Figure 1C) compared with its position under relaxed 
conditions (X2 relaxed;  Figure 1B) forms the basis of numeric 
calculations for SDA. The amplitude of the horizontal shift 
from the relaxed to the contracted situation relative to the 
fixed reference point X1 at the inner canthus was calculated 
as follows:
	∆ X = [(X2 contraction − X1) − (X2 relaxed − X1)]
where ∆X is given in the dimension of pixels in the digital 
photograph. To obtain movement amplitudes in millimeters, 
the value of ∆X is normalized for the number of pixels along 
the length of each 5 mm box in each digital photograph.
Digital photographs were taken at Day 0, before injection 
of BoNT/A, and at Days 1, 2, 3, and 7 post-injection. At 
each time-point, 3 cycles of relaxed muscle tension and 
maximum contraction were captured. The pixels of grid data 
of each photograph were analyzed using Windows PaintTM 
Software.
Statistical analyses, including calculation of means, 
  standard deviations (SD) and P-values of t-tests, were per-
formed using Microsoft ExcelTM Software. The study was 
carried out in accordance with the Declaration of Helsinki 
and its later extensions.
Results
Patients
Thirteen patients were enrolled and included in the study 
(female, n = 12; male, n = 1). The median age of the 
patients was 39 years (range, 19–62 years). Ten of the 
participants had never previously received BoNT/A, 2 had 
not received BoNT/A during the past 12 months, and 1 had 
received BoNT/A 6 months previously but did not show any 
remaining action.
skin displacement analysis
skin displacement before BonT/A injection
Horizontal skin displacement from a relaxed to a contracted 
state above the eyebrow showed a linear correlation up to 
35 mm lateral to the midline; horizontal skin displacement 
started to plateau at 40 and 45 mm (Figures 2A and 2B). 
The mean (±SD) amplitude of horizontal skin displacement 
15 mm lateral to the midline was 3.2 ± 1.0 mm, with a range of 
1.9−4.9 mm (Table 1). The mean (±SD) amplitude of horizontal 
skin displacement doubled at 30 mm lateral to the midline to 
6.5 ± 1.4 mm, with a range of 4.0−8.5 mm (Table 1).
A linear regression analysis of pre-injection horizontal 
skin displacement amplitudes from the midline up to 
35 mm laterally (Table 1 and Figure 2B) was performed 
Figure 2 A) Pre-treatment horizontal skin displacement by maximum glabellar 
contraction in 13 individual patients. Analyzed grid points of interest ran laterally 
from  the  midline,  immediately  above  the  eyebrow.  B)  Mean  values  ±  standard 
deviation of the 13 patients in Figure 2A.
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Table 1 skin displacement amplitudes elicited by maximum fronto-glabellar contraction evaluated immediately above the eyebrow 
from 13 patients prior to injection of BonT/A
Distance from 
midline (mm)
Mean contraction 
amplitude (mm)
Standard deviation 
(mm)
Minimum contraction 
amplitude (mm)
Maximum contraction   
amplitude (mm)
0 −0.3 0.6 −1.3 0.7
5 1.2 0.6 0.3 (6%) 2.3 (46%)
10 2.1 0.8 1.3 (13%) 3.8 (38%)
15 3.2 1.0 1.9 (13%) 4.9 (33%)
20 4.3 1.1 2.4 (12%) 6.3 (32%)
25 5.5 1.3 3.6 (14%) 7.6 (30%)
30 6.5 1.4 4.0 (13%) 8.5 (28%)
35 7.5 1.2 5.0 (14%) 10.3 (29%)
40 8.2 1.2 6.4 (16%) 10.9 (27%)
45 8.3 1.3 6.0 (13%) 11.0 (24%)
Note: Percentages given in parentheses refer to the distance from the midline as given in the first column.
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with the equation [y = m ⋅	x + t], where y is the horizontal 
skin displacement amplitude and x is the distance of the 
point of interest from the midline under relaxed conditions. 
The constant parameters m and x were calculated as 0.22 
and −0.12 mm, respectively, with t close enough to zero 
to support calculating distances from the midline. A slope 
of m = 0.22 resulted in horizontal skin displacement at 
maximum contraction of 22% of the distance to the midline 
under relaxed conditions. For example, a specific point 30 mm 
lateral to the midline under relaxed conditions would be 22% 
closer to the midline under contracted conditions, resulting 
in a new position 23.5 mm lateral from the midline.
BonT/A-induced reduction of fronto-glabellar 
contraction
Figure 3A shows the horizontal skin displacement amplitudes 
from a relaxed to a contracted state for the patient shown 
in Figure 1 at Days 0 (pre-injection), 1, 2, 3, and 7. Skin 
displacement analysis was performed on the grid points 
located immediately above the right eyebrow. Similar to the 
variability of horizontal skin displacement before BoNT/A 
injection in different patients (Figures 2A and 2B), the 
BoNT/A-induced reduction in horizontal skin displacement 
amplitude in the fronto-glabellar area also showed intersubject 
variability. To allow better comparison of BoNT/A action 
kinetics, data obtained at Days 1, 2, 3, and 7 (post-injection) 
were normalized to each subject’s skin displacement data 
obtained at Day 0 (pre-injection).
The horizontal skin displacement profiles of 13 individual 
patients 30 mm lateral to the midline (normalized to pre-
injection values) are shown in Figure 3B. Statistical analysis 
by paired double-sided t-testing revealed that a significant 
reduction in horizontal displacement was detectable at Day 1 
compared with pre-injection data (P = 0.03). The significance 
of the reduction compared with pre-injection data increased 
at Days 2, 3, and 7 post-injection (P , 0.0001 for all versus 
Day 0).
Interindividual variability in the time course of BoNT/A 
action was observed, as were differences in the final level 
of blockage of horizontal contraction at Day 7 (Figure 3B). 
Based on visual assessment, individuals with a slower 
response to BoNT/A injection also had lower maximum 
blockage of horizontal contraction compared with individuals 
who had a rapid reduction in contraction amplitude. 
Comparing the 6 patients with the least blocking action on 
Day 7 with the 6 patients with the strongest blocking action 
on Day 7, the mean (±SD) contraction capability at Day 1 
was 98% ± 17% and 79% ± 17%, respectively, of values 
taken pre-injection (P = 0.08 for between-group comparison). 
At Day 7, mean (±SD) contraction capability was reduced 
to 32% ± 10% and 4% ± 7%, respectively (P = 0.0003 for 
between-group comparison).
On average, a 50% reduction in horizontal skin displacement 
from a relaxed to contracted state at 30 mm lateral to the midline 
was achieved between 2 and 3 days after BoNT/A injection 
(Figure 3C). Specifically, relative to Day 0, the maximum 
horizontal skin displacement 30 mm lateral to the midline 
showed a time-dependent and highly significant (P , 0.001) 
reduction to a mean (±SD) of 62% ± 23% at Day 2, and a further 
reduction to 17% ± 16% at Day 7 (Table 2). Corresponding 
values for maximum horizontal skin displacement 15 mm 
lateral to the midline were 62% ± 29% at Day 2 and 15% ± 20% 
at Day 7 (Table 2). The blockage kinetics was fastest at 20 and 
25 mm, in the middle of the 2 injection points at 15 and 30 mm 
lateral to the midline, whereas points 40 and 45 mm lateral to 
the midline showed a slightly less pronounced reduction in 
horizontal contraction ability (Figure 3D and Table 2); these 
differences were not significant.Clinical, Cosmetic and Investigational Dermatology 2011:4
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Figure  3  Time-dependent  reduction  of  contraction-induced  horizontal  skin 
displacement  after  injection  of  BonT/A.  A)  reduction  of  horizontal  skin 
displacement amplitudes from Day 0 pre-treatment to Day 7 post-treatment of 
the patient shown in Figure 1. Again, analyzed grid points of interest ran laterally 
from the midline, immediately above the eyebrow. B) reduction of horizontal skin 
displacement amplitudes of 13 individual patients at the injection site 30 mm lateral 
to the midline, immediately above the eyebrow (X2, Y2 in Figure 1B, 1C), normalized 
to the individual pre-treatment maximum. C) Mean values ± standard deviation 
of the 13 patients shown in Figure 3B. D) normalized mean reduction of horizontal 
skin displacement amplitudes of 13 patients at points of interest 15−45 mm lateral 
to the midline, immediately above the eyebrow.
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safety
Overall BoNT/A injections were well tolerated. The only 
adverse event reported was a frontal headache in 1 patient 
at Days 1 and 2 after injection.
Discussion
Since the introduction of different preparations of BoNT/A 
to aesthetic medicine,1 studies assessing their effectiveness 
have predominantly relied on semi-quantitative analog scale-
derived evaluation tools.2−6 Electromyography, the standard 
method for evaluation of BoNT/A action on skeletal muscle 
in neurology, does not allow the analysis of BoNT/A action 
with a 2-dimensional resolution of a few millimeters, as is 
frequently required in aesthetic indications. Despite this, 
electromyography has been proposed for the follow-up of 
global BoNT/A action on the frontalis muscle.8 Attempts 
to introduce quantitative image analysis of BoNT/A 
action in aesthetic settings have, so far, been restricted by 
their limitation to the analysis of the mobility of existing 
anatomical structures, such as the evaluation of the eyebrow 
motion or eyebrow height after BoNT/A injections into the 
glabellar area.9,10
To overcome some of the limitations of previous 
evaluation methods, this article describes SDA, a quantitative 
technique that can be used to evaluate skin movements related 
to the insertion and contraction of any given mimetic muscle 
of the face and neck area in any direction. In this study, we 
were able to effectively demonstrate evaluation of horizontal 
skin displacement related to fronto-glabellar contraction. 
Table 2 Time course of average reduction of maximum fronto-
glabellar  contraction  elicited  skin  displacement  amplitudes, 
normalized to Day 0 prior to BonT/A injection
Day 1 Day 2 Day 3 Day 7
15 mm 88 ± 31% 
(43%−152%)
62 ± 29% 
(11%−119%)
45 ± 36% 
(5%−126%)
15 ± 20% 
(−18%−53%)
20 mm 77 ± 16% 
(54%−109%)
58 ± 27% 
(18%−105%)
39 ± 29% 
(5%−93%)
14 ± 18% 
(−14%−51%)
25 mm 76 ± 17% 
(53%−112%)
55 ± 20% 
(25%−82%)
39 ± 25% 
(6%−77%)
14 ± 16% 
(−9%−50%)
30 mm 86 ± 20% 
(57%−118%)
62 ± 23% 
(22%−102%)
44 ± 26% 
(7%−71%)
17 ± 16% 
(−5%−43%)
35 mm 84 ± 17% 
(60%−109%)
67 ± 24% 
(25%−106%)
47 ± 26% 
(6%−84%)
18 ± 16% 
(−3%−43%)
40 mm 86 ± 17% 
(61%−115%)
70 ± 23% 
(27%−113%)
54 ± 28% 
(7%−85%)
19 ± 18% 
(−6%−46%)
45 mm 91 ± 17% 
(72%−124%)
75 ± 22% 
(36%−107%)
61 ± 29% 
(14%−95%)
22 ± 22% 
(5%−29%)
Notes:  Data  obtained  from  points  located  15−45  mm  lateral  to  the  midline, 
immediately above the eyebrow. Values are given as mean ± standard deviation and 
range (min−max) of 13 patients.Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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One of the major advantages of SDA is that it allows the 
evaluation of single points of interest, even those remote 
from anatomical structures such as the eyebrows. The basis 
for SDA is the appropriate marking of the area to be evaluated 
with a suitable marking system or pattern. For simplicity in 
this study, we used a removable grid tattoo. The contraction-
related displacements of single points of the fronto-glabellar 
area were then calculated relative to the coordinates of the 
medial canthus, which served as the fixed-point origin of 
the whole geometric system. Due to the characteristics of 
this evaluation method, even limited vertical or horizontal 
movements of the patient’s head, which could compromise 
results with other methods, were eliminated. Furthermore, 
due to the characteristics of the cosine function, even limited 
rotation of the head had minimal influence on the calculation 
of skin displacements. For example, a clockwise rotation of 
the head of 10° would cause an error of only 1.5% when 
calculating a horizontal skin displacement using the factor 
cos(10°). Additionally, the dimensions of any useful marking 
system, such as the removable grid tattoo with a 5 mm grid 
used in the current study, allows for the calibration of any 
contraction-related skin displacement. In this study, it was 
possible to quantitatively analyze contraction-related skin 
displacement of the fronto-glabellar area.
In general, the horizontal shortening from relaxed to 
contracted state along the length of the corrugator muscle 
was 22% pre-BoNT/A injection, as determined by linear 
regression analysis. The pre-treatment range of shortening 
amongst individual patients varied from 13% to 33%, 
resembling a shortening from one-eighth to one-third 
of the relaxed corrugator muscle length. Interestingly, 
the maximum horizontal contraction amplitude above 
the eyebrow showed a linear correlation to the position 
measured from the midline up to about 35 mm laterally; 
horizontal contraction amplitudes then stabilized at 40 
and 45 mm lateral to the midline (Figure 2B), suggesting 
that the average length of the corrugator muscle did not 
exceed 35 mm.
Close to the midline, evaluation of contraction-induced 
horizontal skin movements showed some limitations. 
Contraction effects are superimposed by shifting and folding 
of excessive skin in a more or less random fashion, finally 
resulting in deep lines and rhytids in the central glabellar area, 
for which BoNT/A injection aims to correct. In our study, at 
the midline, where all horizontal skin movement amplitudes 
should be zero, measured values ranged from −1.3 to 0.7 mm, 
reflecting these ‘random’ skin movements. Furthermore, 
some of the negative skin movement values at the midline 
might have been caused by asymmetrical use of the corrugator 
muscles in an individual patient.
In the current study, regardless of age, mass of corrugator 
muscles, and severity of lines and rhytids, all patients 
received a fixed dose of 18 units of BoNT/A in the fronto-
glabellar area in order to provide standardized conditions 
with the dosage of the drug used. With this moderate dose of 
BoNT/A, a full blockage of mimetic muscles of the fronto-
glabellar area was not expected in all subjects. Therefore, the 
study design was able to provide some interesting information 
in addition to the proof-of-principle of the SDA method. 
Specifically, the limited dose of BoNT/A in relation to the 
individual strength of the corrugator muscle may have been 
the reason that some patients ended up with only about 50% 
blockage of horizontal contraction 7 days after injection, 
while others reached 100% blockage of their horizontal 
fronto-glabellar contraction capability. Interestingly, a slower 
onset of action of BoNT/A after injection seemed to be 
related to less pronounced final blockage of contraction. This 
hypothesis requires confirmation in a specifically designed 
study. Nevertheless, as displayed in Figure 3B, all patients 
showed a reduction in contraction-related skin displacement 
in the horizontal direction 3 days after injection of BoNT/A. 
At Day 7, all patients reached a stronger level of blockage 
of contraction amplitudes.
By extrapolating findings from the current trial, SDA 
could be used in future studies to assess how different doses 
of BoNT/A affect blockage action or how an increased 
or decreased number of injection sites could influence 
blockage of muscle contraction. The method could also be 
used to assess loss of BoNT/A action weeks and months 
after injection. Other potentially interesting fields of study 
could include the analysis of different dilutions of BoNT/A 
and comparisons between different products, including 
between different pharmaceutical or cosmetic substances 
claiming to reduce the activity of mimetic muscles in the 
face or neck area.
Conclusion
We have successfully demonstrated the use of a new method 
for assessing skin movements elicited by muscles inserting 
the overlaying skin. SDA demonstrated high accuracy to 
within a few millimeters when evaluating BoNT/A-induced 
blockage of horizontal contraction in the fronto-glabellar 
area. This method could help to more accurately assess the 
effects of injected BoNT/A in aesthetic indications in the 
face or neck area and to overcome some of the limitations 
of semi-quantitative analog scale-based analyses.Clinical, Cosmetic and Investigational Dermatology
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